For this position, the PhD project will be conducted at two institutions in Barcelona, Spain: the Hospital del Mar Research Institute (HMRIB) and the University of Barcelona, in collaboration with the Bellvitge Biomedical Research Institute (IDIBELL). The selected candidate will be embedded in the POLARIS consortium, with academic supervision and disease-specific expertise provided by Dr Jana Selent at HMRIB and Dr Raul Estévez at the University of Barcelona–IDIBELL.

HMRIB and University of Barcelona–IDIBELL
The Hospital del Mar Research Institute (HMRIB) contributes strong expertise in computational drug discovery, molecular pharmacology and translational biomedical research. In close collaboration, the University of Barcelona and IDIBELL provide complementary expertise in leukodystrophy biology, disease modelling and translational neuroscience. Together, these institutions offer an interdisciplinary environment that bridges target discovery, compound optimisation and disease-relevant validation.
This doctoral project focuses on the discovery, optimisation and functional characterisation of novel GPRC5B modulators through an integrated computational and experimental drug discovery strategy.
GPRC5B is an orphan G protein-coupled receptor implicated in leukodystrophy pathogenesis and brain homeostasis. It represents a promising but still insufficiently explored therapeutic target. The project will combine AI-assisted virtual screening, molecular modelling and experimental validation to identify and optimise novel compounds targeting GPRC5B. The overall aim is to generate new pharmacological tools and candidate molecules that can support the development of innovative therapeutic strategies for leukodystrophies.
The candidate will work at the interface of computational chemistry, molecular pharmacology, translational neuroscience and rare disease research. Planned secondments will provide additional interdisciplinary and intersectoral training within the POLARIS consortium, including exposure to compound optimisation and disease-relevant validation workflows.
The academic embedding will be within the participating institutions in Barcelona, with full participation in the broader POLARIS doctoral training programme.
Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:
- You must not already hold a doctoral degree.
- At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the Netherlands for more than 12 months in the three years prior to the contract start date.
- You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.
We are looking for a motivated candidate with a Master’s degree in pharmacy, chemistry, biomedical sciences, pharmacology, computational biology or a related field. You have a strong interest in interdisciplinary drug discovery, molecular pharmacology and translational research, particularly in the context of rare diseases.
You are interested in understanding how structural and dynamic information on GPCRs can be used to identify and optimise novel GPRC5B modulators. Experience with programming and data analysis, for example in Python, is highly desirable. Familiarity with molecular modelling, docking workflows, machine-learning approaches or high-performance computing is considered an advantage. Experience with cell-based assays, including functional or pharmacological readouts, is also valuable.
Candidates with a primarily computational background and a strong motivation to develop experimental expertise are encouraged to apply. You work accurately and reproducibly, have strong analytical skills and are able to collaborate across disciplines and institutions.
- A contract for 12 months, with the intention to extend for a total of 3 years;
- Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules;
- Embedding in the international POLARIS doctoral training network;
- Access to network-wide training activities, secondments and transferable-skills development;
- A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical therapy development;
- A collaborative and entrepreneurial working environment;
- An open and supportive team culture with opportunities for scientific and professional development.
Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.
POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.













